SCHEMBL2549161

SCHEMBL2549161

Cc1ccc(-c2ccncc2)c2cc(N)ncc12

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.44
FYN P06241 1/20 0.44
NTRK1 P04629 3/20 0.44
MAP4K1 Q92918 1/20 0.41
NOS3 P29474 1/20 0.40
NOS1 P29475 1/20 0.40
NOS2 P35228 1/20 0.40
AURKB Q96GD4 2/20 0.39
INCENP Q9NQS7 2/20 0.39
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39
DYRK1A Q13627 1/20 0.38
BTK Q06187 1/20 0.38
AURKA O14965 1/20 0.36
TTK P33981 1/20 0.36
ADORA2B P29275 1/20 0.36
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15460045 0.80 NOS3 (0.54) ABL1MAP4K1NOS3NOS1NOS2
SCHEMBL9887187 0.73 CYP1A2 (0.54)
SCHEMBL558305 0.73 NOS3 (0.45) ABL1MAP4K1NOS3NOS1NOS2
SCHEMBL2551647 0.73 NOS3 (0.45) ABL1MAP4K1NOS3NOS1NOS2
SCHEMBL12245718 0.71 PRKCZ (0.42) ABL1NTRK1DYRK1A
SCHEMBL31426287 0.69 NOS3 (0.45) ABL1MAP4K1NOS3NOS1NOS2
SCHEMBL15460042 0.69 NOS3 (0.45) ABL1MAP4K1NOS3NOS1NOS2
SCHEMBL6997659 0.68 IMPDH2 (0.49) FYNNTRK1AURKBINCENPPDE3B
SCHEMBL30522562 0.68 IMPDH2 (0.49) FYNNTRK1AURKBINCENPPDE3B
SCHEMBL17571196 0.67 TNF (0.58) DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2552893-B1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-10-29 EP disclosed
US-20130096119-A1 Isoquinolin-3-Ylurea Derivatives BUR DANIEL (CH) 2013-04-18 US disclosed
EP-2552893-A1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2013-02-06 EP disclosed
WO-2011121555-A1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2011-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096119-A1 Isoquinolin-3-Ylurea Derivatives CLIC1, IRF3, KCNH3 ABL1 14/4885FYN 2682/4885NTRK1 4671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.